Novome Biotechnologies (@novomebio) header
Novome Biotechnologies (@novomebio) profile picture

Engineering Living Medicines for Chronic Diseases

South San Francisco, CA
Joined March 2017
Photo by Novome Biotechnologies (@novomebio)Photo by Novome Biotechnologies (@novomebio)Photo by Novome Biotechnologies (@novomebio)Photo by Novome Biotechnologies (@novomebio)Photo by Novome Biotechnologies (@novomebio)Photo by Novome Biotechnologies (@novomebio)
#News: Excited to share we’ve secured $43.5 million in our Series B financing to advance our ongoing Phase 2a clinical trial in #hyperoxaluria and pipeline of #GEMMs candidates for #IBD. Learn more: novomebio.com #celltherapy #livingmedicines
#News: Excited to share positive Phase 1 results of our orally-administered #GEMM, NOV-001, which produced high levels of engraftment of our engineered strain in the GI tract. Learn more here: https://teapawt.net/t.co/Mm76N88lMP #celltherapy #IBD #livingmedicines
3
3
14
#News: Exciting day here as we enter a collaboration with @Genentech to leverage our #GEMMs platform to develop targets against inflammatory bowel disease. Learn more here: https://teapawt.net/t.co/0UyMrcoH2m #celltherapy #IBD #livingmedicines
4
5
12
#News: Excited to share that we’ve appointed Bill McLeod as CFO to broaden our financing experience as we prepare for our next phase of growth. https://teapawt.net/t.co/fYN63I2prB #GEMMs #celltherapy #livingmedicines #CFO
1
4
#News: We’ve dosed our first subject in the Phase 1 clinical trial evaluating our once-daily oral #GEMM candidate for the potential treatment of enteric #hyperoxaluria. https://teapawt.net/t.co/477ybKdenT #GEMMs #celltherapy #gutmicrobiome #livingmedicines
4
2
10
#News: Excited to share we appointed Dr. Lachy McLean as Chief Medical Officer to lead our enteric #hyperoxaluria program into Phase 1/2a proof-of-concept. Learn more here: https://teapawt.net/t.co/1kJCKIqc7T #GEMMs #celltherapy #gutmicrobiome #livingmedicines
3
5
Excited to share the news that Dave Cook (Forma Therapeutics) and Zach Hornby (Boundless Bio) have joined our Board. Looking forward to their contributions as we expand our GEMMs platform to engineer living medicines for chronic diseases! Learn more here: novomebio.com
3
3
We are excited to announce the acquisition of key IP from @CaribouBio, including a license to their CRISPR tools, which will enable new therapeutic opportunities for Novome and accelerate generation of promising therapeutic candidates. Learn more here: globenewswire.com/news-relea…
4
3
10
We're hiring! Looking for excellent Scientists and Research Associates to join our team, engineering gut bacteria as living medicines for chronic diseases. Apply @ novomebiotechnologies.applyt… #hiring #syntheticbiology #synbio #gutbacteria #microbiome #therapeutics
8
13